Next-Generation Treatments for Melanomas
Improvements in survival over the last decade for patients diagnosed with advanced melanoma is largely due to the development of ground-breaking novel treatments, such as the first BRAF inhibitor and checkpoint immunotherapy. Building on the success of these new treatment approaches, researchers are hard at work developing meaningful improvements through next-generation treatments that could improve patient outcomes.
Elizabeth McGowan & Outpedaling 'The Big C'
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 18 September 2020 In Melanoma Stories
To celebrate her fifth anniversary of being NED, Elizabeth McGowan set out on a 4,250- mile adventure across the United States, coined 'Heals on Wheels.' Now, 20-years later, the Pulitzer Prize-winning author shares insight into her journey with melanoma and her solo bicycle trek in her book: "Outpedaling ‘The Big C’: My Healing Cycle Across America."
Integrative Medicine Answers the Question: ‘What Can I Do to Support My Treatment?’
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 24 August 2020 In Science, Treatment
When Dr. Gary Deng sits down with a new patient to discuss their goals and how integrative medicine can fit into their overall treatment plan, he likens his work to taking care of a plant. “With the right amount of water, sunshine, fertilizer, and soil – a plant will thrive. That’s what integrative medicine is looking to do, but with an entire person,” says Deng.
Working to Take the Luck Out of Melanoma
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 16 August 2020 In Melanoma Stories
Ellen believes that research is the best tool we have to “take the luck” out of melanoma. She’s proud to be involved with an organization – and a cause – that is relentlessly moving forward in search of answers, new treatments, and ultimately a cure for melanoma. “I know that given the right support, research will get us there,” she says.
Expanding the Tool Box: New Melanoma Treatment Approaches Being Explored
Despite the tremendous progress made in melanoma treatments over the last 10 years, only about half of such patients respond favorably to current treatments. During the MRA’s Melanoma > Exchange Patient & Advocate Forum, MRA-funded investigators shared updates on emerging science and promising clinical trials.
For Melanoma Researcher Dr. Betina Yanez, It’s All About the Journey
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 27 July 2020 In Science
If you close your eyes and imagine what a melanoma researcher looks like, Dr. Betina Yanez is probably not what you imagine. That’s because Dr. Yanez, a health psychologist by training, isn’t your typical melanoma researcher. Instead of researching new treatment targets or experimental combination therapies, she focuses on patient experience and quality of life.
Putting Her Faith in Research & Her Doctor
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 23 July 2020 In Melanoma Stories, Treatment
All things considered, things are looking up for Margaret Oplinger. A marble-sized tumor is all that’s left of her Stage 4 melanoma; and her ongoing treatment, every-other week with nivolumab (Opdivo®), will hopefully enable her immune system to attack – and eliminate – this last remnant.
Basic Research: Understanding what Triggers Melanoma and its Spread to Identify New Treatment Targets
9 July 2020 In Science
Tremendous progress has been made in understanding the basic biology needed to trigger melanoma and fuel its growth and progression. Researchers continue to probe deeper, finding new molecular culprits that could lead to novel and more effective melanoma treatment strategies. Some of these new potential drug targets were revealed at MRA’s 2020 Scientific Retreat.
Melanoma Research Updates from 2020 AACR and ASCO Conferences
MRA Chief Science Officer Marc Hurlbert shares exciting melanoma research highlights from ASCO and AACR - the two largest global cancer research conferences that take place annually.
Painting a Portrait of the Melanoma Clinical Trial Participant
MRA Chief Science Officer Marc Hurlbert, MRA Director of Communications Cody Barnett, and Antidote's Head of Partnerships Lindsey Wahlstrom-Edwards discuss what matters most to melanoma patients when it comes to participating in clinical trials.